What Is Wegovy?
Wegovy is the brand name for high-dose semaglutide (2.4 mg weekly), manufactured by Novo Nordisk. It was FDA-approved in June 2021 specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition. In March 2024, it received an additional approval for reducing cardiovascular risk in adults with obesity and established heart disease.
The STEP Trials: What the Research Shows
Wegovy's approval was supported by the STEP clinical trial program — a series of large, randomized, placebo-controlled trials. The headline result from STEP 1 was an average weight loss of approximately 15% of body weight over 68 weeks in adults without diabetes. Approximately one-third of participants lost 20% or more of their body weight. These results were unprecedented for a pharmacological intervention.
Titration Schedule
Wegovy follows a 16-week titration: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 1.0 mg for weeks 9–12, 1.7 mg for weeks 13–16, then 2.4 mg maintenance from week 17 onward. This gradual increase is designed to minimize gastrointestinal side effects.
Common Side Effects
- Nausea — affects a majority of users, especially during titration
- Vomiting and diarrhea
- Constipation and stomach pain
- Fatigue, particularly in early weeks
The Cardiovascular Approval: A Milestone
The March 2024 cardiovascular approval for Wegovy was a landmark moment — making it the first obesity medication ever to receive FDA approval for a cardiovascular indication, based on the SELECT trial's 20% reduction in major adverse cardiovascular events.
July 2026 Updates
Oral Wegovy Passes 3 Million Prescriptions: As of the 2026 American Diabetes Association Scientific Sessions, Novo Nordisk reported that prescriptions for the oral semaglutide pill (Wegovy in pill form) have surpassed 3 million — roughly one filled every 5 seconds — bringing GLP-1 therapy to people with obesity who previously went untreated or who avoided injections.
Semaglutide and Biological Aging (July 2026): A randomized, placebo-controlled clinical trial published in July 2026 found that semaglutide slowed biological aging markers in adults with HIV — the first prospective human evidence that Wegovy's active ingredient may influence the pace of biological aging, not just weight. Research is early-stage but has generated significant scientific attention.
Medicare GLP-1 Bridge (Launched July 1, 2026): CMS launched a short-term demonstration program allowing eligible Medicare Part D beneficiaries to access certain GLP-1 weight loss medications — including Wegovy — for approximately $50/month. The program runs through December 31, 2027 and is managed through a central processor outside of standard Part D coverage flow. Talk to your pharmacist or prescriber about eligibility.
Making the Most of Wegovy
Wegovy works best when paired with meaningful nutrition and activity changes. The medication significantly suppresses appetite, making it essential to maximize nutritional value of the meals you do eat. High protein intake to preserve muscle mass, adequate hydration, and a structured meal plan are the three most impactful nutritional habits for people on Wegovy. ShedPilot is built for exactly this.